Page last updated: 2024-12-05

pramoxine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pramoxine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pramocaine : A member of the class of morpholines that is morpholine substituted at the nitrogen atom by a 3-(4-butoxyphenoxy)propyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4886
CHEMBL ID1198
CHEBI ID8357
SCHEMBL ID26020
MeSH IDM0047166

Synonyms (81)

Synonym
LS-14605
BRD-K46523383-003-04-7
pramocainum
proxazocain
gamma-morpholinopropyl 4-n-butoxyphenyl ether
p-butoxyphenyl gamma-morpholinopropyl ether
CHEBI:8357 ,
4-[3-(4-butoxyphenoxy)propyl]morpholine
KBIO1_000882
DIVK1C_000882
einecs 205-425-7
pramocaina [inn-spanish]
4-(3-(p-butoxyphenoxy)propyl)morpholine
tronopthane
4-(3-(4-butoxyphenoxy)propyl)morpholine
pramocaine [inn:ban]
pramocainum [inn-latin]
brn 0239059
SPECTRUM_001380
morpholine, 4-[3-(4-butoxyphenoxy)propyl]-
morpholine, 4-(3-(p-butoxyphenoxy)propyl)-
NCGC00016529-01
cas-637-58-1
BPBIO1_001025
SPECTRUM5_001511
PRESTWICK2_000716
IDI1_000882
BSPBIO_000931
AB00053605
C07892
140-65-8
pramocaine
pramoxine
KBIO2_004428
KBIOGR_001547
KBIO3_001930
KBIO2_006996
KBIO2_001860
KBIOSS_001860
SPECTRUM2_000030
SPECTRUM4_001024
SPECTRUM3_000925
PRESTWICK0_000716
SPBIO_002852
PRESTWICK1_000716
NINDS_000882
SPBIO_000099
PRESTWICK3_000716
NCGC00016529-02
CHEMBL1198
pramocaine (inn)
D08407
NCGC00016529-03
NCGC00016529-04
unii-068x84e056
pramocaina
4-27-00-00127 (beilstein handbook reference)
068x84e056 ,
pramocaine [who-dd]
pramoxine [mi]
pramocaine [inn]
pramoxine [vandf]
SCHEMBL26020
4-[3-(4-butoxyphenoxy)propyl]morpholine #
p-butoxyphenyl .gamma.-morpholinopropyl ether
.gamma.-morpholinopropyl 4-n-butoxyphenyl ether
DQKXQSGTHWVTAD-UHFFFAOYSA-N
px9 ,
AB00053605_13
AB00053605_14
DTXSID8040692 ,
DB09345
SBI-0051653.P002
bdbm50225493
Q1240076
EN300-18530975
pramocaina (inn-spanish)
d04ab07
pramocainum (inn-latin)
dtxcid6020692
c05ad07

Research Excerpts

Effects

ExcerptReferenceRelevance
"Pramoxine has been shown to produce spinal anesthesia, while cutaneous analgesia (peripheral) of pramoxine is not established. "( Skin nociceptive block with pramoxine delivery by subcutaneous injection in rats.
Chen, YW; Chiu, CC; Chou, AK; Hung, CH; Wang, JJ, 2018
)
2.22
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
local anaestheticAny member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
morpholinesAny compound containing morpholine as part of its structure.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency8.91250.011212.4002100.0000AID1030
mitogen-activated protein kinase 1Homo sapiens (human)Potency15.84890.039816.784239.8107AID995
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.12100.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.05100.00000.490110.0000AID625223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1061889Displacement of [3H]BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes after 60 mins by scintillation counting2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: design of potent new ligands.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (34.21)18.7374
1990's3 (7.89)18.2507
2000's9 (23.68)29.6817
2010's11 (28.95)24.3611
2020's2 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.46 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index150.40 (26.88)
Search Engine Supply Index3.49 (0.95)

This Compound (54.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (14.89%)5.53%
Reviews6 (12.77%)6.00%
Case Studies7 (14.89%)4.05%
Observational1 (2.13%)0.25%
Other26 (55.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of PRAX-114 in the Treatment of Adults With Essential Tremor [NCT05387642]Phase 20 participants (Actual)Interventional2022-04-05Withdrawn(stopped due to Sponsor no longer pursuing indication.)
A Phase 2 Double-blind, Placebo-Controlled, Dose-Ranging Clinical Trial to Evaluate the Efficacy and Safety of PRAX-114 in Adjunctive and Monotherapy Treatment of Participants With Major Depressive Disorder and Inadequate Response to Antidepressant Treatm [NCT04969510]Phase 2110 participants (Actual)Interventional2021-06-24Completed
A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy [NCT05737784]Phase 1/Phase 260 participants (Anticipated)Interventional2023-02-28Recruiting
A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants With Developmental and Epileptic Encephalopathies Followed by Open-Label Extension(OLE) [NCT05818553]Phase 220 participants (Anticipated)Interventional2023-04-11Recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of PRAX-944 in the Treatment of Adults With Essential Tremor [NCT05021991]Phase 2131 participants (Anticipated)Interventional2021-10-14Active, not recruiting
The Safety of Proctofoam-HC in the Third Trimester of Pregnancy [NCT00405288]408 participants (Actual)Observational2006-11-30Completed
A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults With Essential Tremor [NCT05021978]Phase 224 participants (Actual)Interventional2020-03-03Completed
A Phase 2, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PRAX-114 in Participants With Post-Traumatic Stress Disorder [NCT05260541]Phase 211 participants (Actual)Interventional2022-01-25Terminated(stopped due to No longer developing for this indication)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00405288 (12) [back to overview]Birth-weight
NCT00405288 (12) [back to overview]Gestational Age at Delivery
NCT00405288 (12) [back to overview]Cardiovascular Neonatal Health Concerns in the First Two Weeks After Birth
NCT00405288 (12) [back to overview]Fetal Distress
NCT00405288 (12) [back to overview]Low Birth Weight at Birth
NCT00405288 (12) [back to overview]Mode of Delivery
NCT00405288 (12) [back to overview]Neonatal Health
NCT00405288 (12) [back to overview]Neonatal Health Concerns-infections
NCT00405288 (12) [back to overview]Other Neonatal Health Concerns
NCT00405288 (12) [back to overview]Prematurity
NCT00405288 (12) [back to overview]Respiratory Neonatal Health Concerns
NCT00405288 (12) [back to overview]Skin Conditions in Neonatal Period

Birth-weight

Weight of the baby measured in grams at time of birth. (NCT00405288)
Timeframe: until delivery

Interventiongrams (Mean)
Proctofoam-HC®3406.9
Control3487.7

[back to top]

Gestational Age at Delivery

Fetal gestational age at delivery (NCT00405288)
Timeframe: until delivery

Interventiongestational weeks (Mean)
Proctofoam-HC®39.4
Control39.1

[back to top]

Cardiovascular Neonatal Health Concerns in the First Two Weeks After Birth

Assessment of neonate's morphology and function of cardiovascular system in the first two weeks after birth (NCT00405288)
Timeframe: neonatal period

,
Interventionparticipants (Number)
Cardiovascular anomaliesHeart murmurPremature atrial contraction
Control042
Proctofoam-HC®260

[back to top]

Fetal Distress

Presence of fetal distress at birth: heart deceleration/acceleration, meconium/amniotic fluid (NCT00405288)
Timeframe: at birth

,
Interventionparticipants (Number)
Fetal distressNo fetal distress
Control31142
Proctofoam-HC®36163

[back to top]

Low Birth Weight at Birth

Low birth weight (birth weights <2500 grams) (NCT00405288)
Timeframe: at birth

,
Interventionparticipants (Number)
YesNo
Control3198
Proctofoam-HC®6194

[back to top]

Mode of Delivery

Method of delivery for both groups: vaginal or caesarean section (NCT00405288)
Timeframe: at birth

,
Interventionparticipants (Number)
Vaginal deliveryCaesarean sectionUnknown
Control146553
Proctofoam-HC®173310

[back to top]

Neonatal Health

Neonatal health at birthyes=need for medical attention or intervention after birth, abnormalities detected, no= no need for medical attention, no abnormalities detected at birth (NCT00405288)
Timeframe: at birth

,
Interventionparticipants (Number)
Yes (present neonatal health concerns)No (absent neonatal health concerns)
Control24154
Proctofoam-HC®28171

[back to top]

Neonatal Health Concerns-infections

Infections occuring in the neonatal period (NCT00405288)
Timeframe: neonatal period

,
Interventionparticipants (Number)
Urinary tract infectionsStreptococcus B infectionPneumoniaLeucocytosis
Control0220
Proctofoam-HC®2002

[back to top]

Other Neonatal Health Concerns

(NCT00405288)
Timeframe: neonatal period

,
Interventionparticipants (Number)
ConjuctivitisMyopiaColicMilk allergyHypoglycemiaPoor feedingPoor weight gainAnemiaRenal calculi
Control024200222
Proctofoam-HC®400042200

[back to top]

Prematurity

birth at <37 gestational weeks (NCT00405288)
Timeframe: at birth

,
Interventionparticipants (Number)
yesno
Control10180
Proctofoam-HC®8193

[back to top]

Respiratory Neonatal Health Concerns

(NCT00405288)
Timeframe: neonatal period

,
Interventionparticipants (Number)
Pulmonary aspirationMild asthmaTachypnea
Control022
Proctofoam-HC®420

[back to top]

Skin Conditions in Neonatal Period

(NCT00405288)
Timeframe: neonatal period

,
Interventionparticipants (Number)
RashEczemaAcne
Control222
Proctofoam-HC®200

[back to top]